We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 7.00
Ask: 7.95
Change: 0.55 (7.94%)
Spread: 0.95 (13.571%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 6.925
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Statement and COVID-19 Update

4 May 2020 07:00

RNS Number : 7390L
Carclo plc
04 May 2020
 

Carclo plc

("Carclo" or "the Group" or "the Company")

 

Full Year Trading Statement and COVID-19 Update

 

Trading update for the year ended 31 March 2020 ("FY2020")

 

The Board is pleased to announce that trading for the continuing businesses during the second half of FY2020 reflected a continuation of the positive momentum seen in the first half of the year. Consequently, the Board expects to report, subject to audit, underlying results for the continuing businesses for FY2020 in line with its expectations.

 

The Technical Plastics Division performed strongly for the year as a whole, largely driven by increased volume as the business continued to secure a number of new programmes in its core medical market. The Aerospace Division also performed well, driven by increased volumes of spares orders and customers building inventory ahead of the UK's exit from the EU.

 

As previously announced, the Group successfully completed the exit from the loss-making businesses of the LED Division in December 2019.

 

The Group's net debt (including IFRS16 leases and subject to audit) at 31 March 2020 was £25.8m, (30 September 2019: £31.7m).

 

Impact of COVID-19

 

Whilst the initial outbreak of COVID-19 had limited impact on trading in final quarter of FY2020, disruption has been more extensive in the first quarter of the current financial year. During this period, the Group's primary focus has been to ensure the wellbeing of staff and the continued safe operation of its businesses. All applicable government advice has been followed across the different countries in which the Group operates. Pleasingly, it has been possible to keep most sites operational through the lockdown period, enabling the Group to continue to serve its customers many of whom operate in essential industries, particularly the medical diagnostic sector.

 

Given the division's focus on the medical market, overall demand across the Technical Plastics business has remained relatively resilient, with a number of its products being used directly in COVID-19 testing applications. Notwithstanding continued demand, the implementation of governmental guidance on social distancing and some limited shutdowns have impacted efficiency and throughput across the Group, which will inevitably have a negative impact on profitability. 

 

Demand for the Aerospace business has been significantly impacted by the downturn in the aerospace sector.

 

Management has already taken action to mitigate these challenges, including accessing government support programmes where available and a reduction in variable costs where appropriate. The Board has taken a 20% cut in fees and salaries for the first quarter of the new financial year. The Group remains focused on ensuring operational continuity where it can; however, it remains very difficult to predict how the ongoing crisis will affect performance going forward. 

 

Outlook

Given the current levels of uncertainty it is not possible for the Board to provide near-term guidance on expected financial performance. As previously reported, discussions continue with the Group's lending bank and pension trustees in order to agree a long-term financing position for Carclo. Whilst these negotiations remain ongoing, there can be no certainty that a satisfactory and affordable agreement will be reached. The Group will make further announcements as appropriate.

Timing of full year results

 

Mindful of the ongoing uncertainty presented by the COVID-19 situation, and the guidance from the Financial Conduct Authority that public companies should consider delaying preliminary announcements, the Board has decided to delay the publication of the Company's Full Year Results for the year ended 31 March 2020 beyond 30 June 2020, the date on which Carclo had previously expected to announce. The revised publication date will be published in due course.

 

Rights attaching to listed equity shares

In compliance with Listing Rule 9.2.6ER(1), the Company has forwarded to the FCA for publication a copy of its Articles of Association, which is the document that sets out the terms and conditions on which its listed equity shares were issued.

A copy of the Articles of Association have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

 

About Carclo plcCarclo plc is a public company whose shares are quoted on the Main Market of the London Stock Exchange. The Group is a global provider of value-adding engineered solutions for the medical, optical and aerospace industries.

 

 

Enquiries:

Carclo plc 01924 268040

Matt Durkin-Jones - Chief Financial Officer

 

FTI Consulting 020 3727 1340

Nick Hasell / Susanne Yule

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKZGGKNFZGGZM
Date   Source Headline
17th Apr 20247:55 amRNSDirectorate Change
15th Apr 20243:55 pmRNSHolding(s) in Company
28th Feb 20247:00 amRNSDirectorate Change
14th Feb 20247:00 amRNSStrategic Consolidation & Tucson Facility Closure
9th Feb 20241:15 pmRNSHolding(s) in Company
29th Jan 202411:09 amRNSDirectorate Change
23rd Jan 20244:48 pmRNSHolding(s) in Company
6th Dec 202310:53 amRNSHolding(s) in Company
30th Nov 20237:00 amRNSHalf-year Report
16th Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
25th Oct 20233:16 pmRNSCarclo Strategic Decision to Close Derry Facility
22nd Sep 20237:00 amRNSDirector/PDMR Shareholding
31st Aug 20234:01 pmRNSResult of AGM
31st Aug 20237:00 amRNSTrading Update
21st Aug 20231:09 pmRNSDirectorate Change
31st Jul 202311:42 amRNSAnnual Financial Report
18th Jul 20237:00 amRNSBanking covenant update
12th Jul 20237:00 amRNSFinal Results
7th Jul 20237:00 amRNSNotice of Investor Meet Presentation
23rd Jun 20237:00 amRNSBanking covenant adjustment
21st Jun 20231:08 pmRNSNotice of Results
30th May 202310:07 amRNSUpdate on contract cancellation
17th May 20238:46 amRNSHolding(s) in Company
12th May 20239:38 amRNSHolding(s) in Company
14th Apr 20237:00 amRNSTrading Statement
31st Mar 202312:50 pmRNSBanking Covenant update
9th Mar 20239:56 amRNSHolding(s) in Company
24th Feb 20237:00 amRNSDirectorate Change
6th Jan 20234:17 pmRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20221:15 pmRNSDirector/PDMR Shareholding
16th Dec 20221:11 pmRNSDirector/PDMR Shareholding
16th Dec 20221:10 pmRNSDirector/PDMR Shareholding
15th Dec 20227:00 amRNSTrading Update
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 20229:44 amRNSContract Cancellation
6th Dec 20226:29 pmRNSHolding(s) in Company - Replacement
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
30th Nov 20227:00 amRNSHalf-year Report
15th Nov 20227:05 amRNSNotice of Interim Results & Investor Presentation
15th Nov 20227:00 amRNSDirectorate Change
7th Nov 20227:00 amRNSBoard Changes
18th Oct 20227:00 amRNSTrading Update
13th Oct 20221:22 pmRNSHolding(s) in Company
6th Oct 20221:05 pmRNSAppointment of Chief Executive Officer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.